Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4565 - Advanced ovarian cancer: is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?


29 Sep 2019


Poster Display session 2


Tumour Site

Ovarian Cancer


Michele Bartoletti


Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


M. Bartoletti1, S. Gagno2, E. Poletto3, M. Garziera2, S. Scalone4, E. Dreussi2, C. Zanusso2, R. Roncato2, E. Cecchin2, E. De Mattia2, R. Sorio4, G. Giorda5, L. Quartuccio6, S. De Vita6, C. Romualdi7, F. Puglisi1, G. Toffoli2

Author affiliations

  • 1 Department Of Medicine (dame), University Of Udine, Udine, Italy; Dipartimento Di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 - Aviano/IT
  • 2 Experimental And Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, 33081 - Aviano/IT
  • 3 Department Of Oncology, Azienda Sanitaria Universitaria Integrata di Udine - Ospedale Santa Maria della Misericordia, 33100 - Udine/IT
  • 4 Department Of Medical Oncology, Centro di Riferimento Oncologico - CRO, 33081 - Aviano/IT
  • 5 Gynaecological Oncology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, 33081 - Aviano/IT
  • 6 Clinic Of Rheumatology, Department Of Medical Area, University Hospital “Santa Maria della Misericordia", 33100 - Udine/IT
  • 7 Department Of Biology, University of Padova, 35122 - Padova/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4565


The residual disease (RD) after debulking surgery is one of the strongest prognostic factors in ovarian cancer (OC) patients. Despite surgical efforts, most patients do not achieve "optimal" cytoreduction (R0) even in high-volume centres. The interplay between cancer-promoted angiogenesis and host immune-system could foster cancer dissemination, reducing the likelihood of surgical eradication. The aim of this study was to assess whether the presence of germline polymorphisms in genes involved in angiogenesis and immunity pathways was predictive of R0.


A cohort of 230 patients with stage III-IV, high grade epithelial OC treated with debulking surgery and platinum-based therapy without bevacizumab, was retrospectively enrolled. A panel of 192 single nucleotide polymorphisms (SNPs) in 34 angiogenesis and immune system-related genes was analyzed with Illumina GoldenGate Genotyping Assay. Log-additive, dominant and recessive genetic models were evaluated using a multivariate logistic regression adjusted for type of surgery (i.e. primary or interval). False discovery rate (FDR) test<0.2 was used for multiple testing data correction.


Thirteen SNPs were significantly associated with RD. Among them, MMP3-rs569444, TLR3-rs5743303 and VEGFA-rs2146323 passed the FDR filter. Patients carrying the variant alleles of MMP3-rs569444 (OR = 2.52, 95%CI 1.42-4.47, p = 0.0326) and VEGFA-rs2146323 (OR = 1.83, 95%CI 1.21-2.75, p = 0.0375) showed an increased risk of RD. Conversely, TLR3-rs5743303 carriers were more likely to achieve R0 (OR = 0.43, 95%CI 0.27-0.7, p = 0.0004).


Angiogenesis and the immune-system competence are key players in OC growth and could influence the burden of RD. In our cohort, individual polymorphisms on angiogenesis (VEGFA), extracellular matrix degradation (MMP3) and innate immunity activation (TLR3) pathways were independent predictive factors of RD. These markers, whether validated, might underline the role of host genetics factors in predicting R0. Moreover, if VEGFA-rs2146323 variant carriers could benefit the most from bevacizumab appears as an intriguing question.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Toffoli Giuseppe.


Has not received any funding.


F. Puglisi: Honoraria (self), Advisory / Consultancy: Amgen; Advisory / Consultancy: Celgene; Advisory / Consultancy: Eisai; Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Ipsen; Advisory / Consultancy, Research grant / Funding (self): Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self): Pierre Fabre; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Takeda; Research grant / Funding (self): AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.